Phase Holographic Imaging (PHI), a leading medical technology company, is excited to announce its official listing on the OTCQB Venture Market in the United States. Trading commenced on Thursday, August 15th, marking a significant milestone in PHI’s expansion and accessibility for US investors.
This listing allows PHI to reach a broader audience of investors, further enhancing its engagement and growth potential. With the symbol “PHIXF”, PHI’s shares are now traded on the OTCQB, a regulated market operated by OTC Markets Group. This platform offers global companies, like PHI, the opportunity to make their shares more accessible to US investors.
The move to the OTCQB represents a crucial step for PHI, promoting more transparent trading practices and catering to the growing demand from US investors. PHI, already listed on the Spotlight Stock Market, can leverage its existing reporting standards to meet US requirements on the OTCQB. This streamlined process simplifies information sharing with US investors.
To qualify for trading on the OTCQB, PHI has met strict financial standards, adhered to best practice corporate governance, and demonstrated compliance with applicable securities laws.
Patrik Eschricht, CEO of PHI, expressed his enthusiasm about the listing: “We are thrilled to expand our market presence by listing on the OTCQB. This new platform offers our investors greater accessibility and visibility in the US market, aligning with our mission to advance regenerative medicine. This dual listing is expected to enhance liquidity, provide greater value to our shareholders, and support the continued growth of PHI.”
About PHI
Phase Holographic Imaging (PHI) is a medical technology company dedicated to developing and marketing non-invasive, time-lapse imaging instruments for long-term quantitative analysis of living cells. Their flagship product, the HoloMonitor®, utilizes Quantitative Phase Imaging (QPI) technology, a revolutionary approach to cell quality evaluation.
QPI enables detailed analysis of cell characteristics without causing harm, overcoming the limitations of traditional measurement methods. PHI is actively expanding its reach from pre-clinical research into the clinical market and the burgeoning regenerative medicine field.
PHI envisions transforming live cell analysis and establishing QPI as the standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI has offices in Lund, Sweden, Boston, Massachusetts, and Winston-Salem, North Carolina.
More Information:
Lisa Bodily, Head of IR, ir@phiab.com, +46 73 026 87 87
www.phiab.com
